Bioactivities and Secondary Structures of Constrained Analogues of Human Parathyroid Hormone:  Cyclic Lactams of the Receptor Binding Region

In a search for analogues of human parathyroid hormone (hPTH) with improved activities and bioavailabilities, we have prepared the following three lactam analogues of hPTH-(1−31)-NH2 (1) or [Leu27]hPTH-(1−31)-NH2 (2):  [Leu27]cyclo(Glu22−Lys26)-hPTH-(1−31)-NH2 (3), [Leu27]cyclo(Lys26−Asp30)-hPTH-(1−...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 1997-04, Vol.40 (9), p.1373-1380
Main Authors: Barbier, Jean-René, Neugebauer, Witold, Morley, Paul, Ross, Virginia, Soska, Mark, Whitfield, James F, Willick, Gordon
Format: Article
Language:English
Subjects:
Adenylyl Cyclases - metabolism
Amino Acid Sequence
Amino Acids - analysis
Animals
Antihypertensive Agents - chemical synthesis
Antihypertensive Agents - chemistry
Antihypertensive Agents - metabolism
Antihypertensive Agents - pharmacology
Biological and medical sciences
Blood Pressure - drug effects
Circular Dichroism
Enzyme Activation
Hormones. Endocrine system
Humans
Lactams - chemical synthesis
Lactams - chemistry
Lactams - metabolism
Lactams - pharmacology
Medical sciences
Models, Molecular
Molecular Sequence Data
Osteoblasts - enzymology
Parathyroid Hormone - chemistry
Parathyroid Hormone - metabolism
Parathyroid Hormone - pharmacology
Peptide Fragments - chemical synthesis
Peptide Fragments - pharmacology
Pharmacology. Drug treatments
Protein Conformation
Protein Structure, Secondary
Rats
Receptors, Parathyroid Hormone - metabolism
Tumor Cells, Cultured
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a search for analogues of human parathyroid hormone (hPTH) with improved activities and bioavailabilities, we have prepared the following three lactam analogues of hPTH-(1−31)-NH2 (1) or [Leu27]hPTH-(1−31)-NH2 (2):  [Leu27]cyclo(Glu22−Lys26)-hPTH-(1−31)-NH2 (3), [Leu27]cyclo(Lys26−Asp30)-hPTH-(1−31)-NH2 (4), and cyclo(Lys27−Asp30)-hPTH-(1−31)-NH2 (5). Analogues 1, 2, and 5 had seven or eight residues of α-helix, as estimated from their circular dichroism (CD) spectra, in contrast to 12 residues in cyclic analogues 3 and 4. Thus, lactams 3 and 4 stabilized a helix previously shown to exist within residues 17−29. The adenylyl cyclase activity (EC50), measured in rat osteosarcoma 17/2 cells, of 5 (40.3 ± 2.3 nM) was half that of its linear form 1 (19.9 ± 3.9 nM). The linear Leu27 mutant 2 was twice as active (11.5 ± 5.2) as analogue 1, and lactam analogue 3 was 6-fold more active (3.3 ± 0.3 nM). Lactam analogue 4 had less activity (16.9 ± 3.3 nM) than 2, its linear form. Peptides hPTH-(1−30)-NH2 (6), [Leu27]hPTH-(1−30)-NH2 (7), and [Leu27]cyclo(Glu22−Lys26)-hPTH-(1−30)-NH2 (8) all had AC-stimulating activities similar to that of 1. When injected intravenously, with a dose of 0.8 nmol/100 g of analogue in acid saline, hypotensive effects paralleled their adenylyl cyclase activities. They behaved quite differently when applied subcutaneously. Analogues 1, 5, and 6, the weakest, showed about half the drop in blood pressure observed with 3 and 4, the most active. In contrast, the time required to reach a maximum drop in blood pressure of 4−8, after subcutaneous administration, was 2−4 times that of the other analogues. Thus, the bioavailabilities of the lactam analogues, unlike their adenylyl cyclase-stimulating activities, were highly dependent on the presence or conformation of Val31.
ISSN:0022-2623
1520-4804
DOI:10.1021/jm960743o